Sign In
20 Nov 2013 17:00
20 November 2013
Grant of Options and Additional Listing
On 19 November 2013, Tim Freeborn (Finance Director and Company Secretary) and Annie Cheng (Chief Operating Officer) were granted 40,000 and 76,000 options respectively over ordinary shares of 5 pence. The share options, granted at nil consideration, will vest after three years and are exercisable at 282 pence per share (the previous day's closing price), and are subject to a 400p hurdle price.
Following this grant of these options, Tim Freeborn and Annie Cheng hold the following total number of options over ordinary shares of Silence Therapeutics:
No. of Options | |
Tim Freeborn | 310,000 |
Annie Cheng | 140,000 |
The Company also announces that it has applied to AIM for the admission to trading of 48,000 Ordinary Shares of 5 pence each in the company. These shares are being issued in respect of an exercise of options under the Employee Share Scheme, at an exercise price of 90 pence per share.
Admission of these shares is expected to take place on Monday 25 November 2013. The total number of shares in issue, following admission, will be 47,061,554.
For further information please contact:
Silence Therapeutics plc Ali Mortazavi, Chief Executive | +44 (0)333 988 0140 a.mortazavi@silence-therapeutics.com |
Timothy Freeborn, Finance Director | t.freeborn@silence-therapeutics.com |
Annie Cheng, Chief Operating Officer
| a.cheng@silence-therapeutics.com |
Canaccord Genuity Limited | +44 (0)20 7523 8350 |
Lucy Tilley Dr Julian Feneley Henry Fitzgerald-O'Connor |
Follow the stocks
